Community Practice Connections™: Translating Recent Evidence on CAR T-Cell Therapy to the Real-World Management of Lymphoid Malignancies
View More
7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards
View More
Evolving Paradigms in Transplant-Related CMV Prevention and Management: Setting Foundations for Improved Patient Outcomes
View More
Evolving Paradigms in Transplant-Related CMV Prevention and Management: Setting Foundations for Improved Patient Outcomes
View More
CAR T-Cell Therapy in Multiple Myeloma: Key Considerations for Patient Selection, Transplant, and Applying Recent Data
View More
Optimizing ASCT in Patients With Multiple Myeloma and Non-Hodgkin Lymphoma Through Stem Cell Mobilization Techniques
View More
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early Stage Breast Cancer When the Goal is Cure
View More
Olvi-Vec Induces Promising Response in Advanced Ovarian Cancer
Olvimulogene nanivacirepvec virotherapy plus chemotherapy with or without bevacizumab produces a manageable safety profile in platinum-resistant or platinum-refractory ovarian cancer in the phase 2 VIRO-15 trial.
The ‘Golden Age’ of Daratumumab: Highlights From an Expert Panel on Multiple Myeloma
June 8th 2023A Satellite Sessions program at the Yale Cancer Center discusses treatment paradigms and unmet needs in multiple myeloma as well as transplantation, bispecific T-cell engaging therapies, and the importance of collaborative decision-making in clinical practice.
FDA Accepts sBLA for Pembrolizumab/Chemo in Advanced Biliary Tract Cancer
The regulatory agency has set a Prescription Drug User Fee Act date of February 7, 2024 for pembrolizumab plus chemotherapy as a treatment for patients with advanced or metastatic biliary tract cancer.
EGFR/HER3 Bispecific Yields Activity in EGFR+ NSCLC, Other Tumor Types
BL-B01D1 may produce promising antitumor activity in a heavily pretreated population of patients with EGFR-mutated non–small cell lung cancer, according to an expert at University Cancer Center in Guangzhou, China.
Epcoritamab Regimen Yields Remission in High-Risk R/R Follicular Lymphoma
June 7th 2023The responses to epcoritamab plus rituximab/lenalidomide for patients with relapsed/refractory follicular lymphoma appear comparable between those with and without disease progression within 24 months of first-line chemotherapy in the phase 1/2 EPCORE NHL-2 trial.
Liso-Cel Yields Encouraging Responses in Relapsed/Refractory CLL/SLL
June 7th 2023Treatment with lisocabtagene maraleucel correlates with a reduction in CD19-positive cells in responders and patients with stable disease among those with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the phase 1/2 TRANSCEND CLL 004 trial.
Tumor Treating Fields Plus SOC May Benefit OS in Metastatic NSCLC
June 7th 2023The results of the phase 3 LUNAR trial evaluating tumor treating fields plus standard-of-care therapies among patients with metastatic non–small cell lung cancer are “encouraging,” according to an expert from Winship Cancer Institute of Emory University.
Dostarlimab Earns Priority Review From FDA In Advanced Endometrial Cancer
June 6th 2023The FDA accepts a supplemental biologics license application for dostarlimab plus chemotherapy in the treatment of mismatch repair deficient/microsatellite instability-high advanced or recurrent endometrial cancer based on data from a prespecified interim analysis of the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial.
No Improvement in OS With Extended Vs Standard Lymphadenectomy in MIBC
June 6th 2023Findings from the phase 3 SWOG S1011 trial highlight no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.